ArticleEuropean journal of pain (London, England)2025
Locus Coeruleus MR Measured Signal Intensity in Fibromyalgia Relative to Healthy Controls.
Article in European journal of pain (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Locus Coeruleus MR Measured Signal Intensity in Fibromyalgia Relative to Healthy Controls.European journal of pain (London, England) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundFibromyalgia is a chronic pain condition without an established aetiology. However, noradrenergic dysfunction is a possible mechanism to explain the constellation of symptoms associated with fibromyalgia. Noradrenaline synthesis in the locus coeruleus (LC) results in a paramagnetic by-product, neuromelanin. Recently, a magnetic resonance imaging sequence sensitive to neuromelanin has been used to assay LC signal intensity, a proxy for noradrenergic system function. Here, we use MR imaging to investigate the noradrenergic-locus coeruleus system in participants with fibromyalgia and healthy controls.
methodsForty-six participants with fibromyalgia and 41 healthy controls were recruited for a cross-sectional characterisation of LC signal intensity at 3 T, quantified from a 2D gradient echo acquisition. Participants completed the Revised Fibromyalgia Impact Questionnaire, as well as measures of anxiety, depression, sleep and the THINC-it cognitive battery.
resultsAn independent groups t-test revealed no differences in LC signal intensity between participants with fibromyalgia and healthy controls. For the participants with fibromyalgia, partial correlations accounting for age showed no association between LC signal intensity and fibromyalgia history, fibromyalgia symptom severity, anxiety, depression, insomnia or cognitive performance. Almost 90% of participants with fibromyalgia had been exposed to medications targeting noradrenergic function complicating the interpretation of these findings.
conclusionsLC signal intensity as measured by MR did not distinguish participants with fibromyalgia and healthy controls, nor was it associated with core fibromyalgia pain symptoms or associated symptoms. Dynamic measures of noradrenergic function may be required to understand noradrenergic contributions to fibromyalgia. SIGNIFICANCE STATEMENT: This study is the first report using MR measured signal intensity of the LC to examine noradrenergic function in participants with fibromyalgia. There was no difference in signal intensity when comparing patients to controls, nor did it associate with any symptoms or associated features of fibromyalgia. This suggests that lifetime noradrenergic function may not distinguish fibromyalgia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.